565 related articles for article (PubMed ID: 35422101)
1. The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.
Alarcón-Zendejas AP; Scavuzzo A; Jiménez-Ríos MA; Álvarez-Gómez RM; Montiel-Manríquez R; Castro-Hernández C; Jiménez-Dávila MA; Pérez-Montiel D; González-Barrios R; Jiménez-Trejo F; Arriaga-Canon C; Herrera LA
Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):431-443. PubMed ID: 35422101
[TBL] [Abstract][Full Text] [Related]
2. Genomics and Artificial Intelligence: Prostate Cancer.
Wong EY; Chu TN; Ladi-Seyedian SS
Urol Clin North Am; 2024 Feb; 51(1):27-33. PubMed ID: 37945100
[TBL] [Abstract][Full Text] [Related]
3. Circulating RNAs in prostate cancer patients.
Mugoni V; Ciani Y; Nardella C; Demichelis F
Cancer Lett; 2022 Jan; 524():57-69. PubMed ID: 34656688
[TBL] [Abstract][Full Text] [Related]
4. Genomic Markers in Prostate Cancer Decision Making.
Cucchiara V; Cooperberg MR; Dall'Era M; Lin DW; Montorsi F; Schalken JA; Evans CP
Eur Urol; 2018 Apr; 73(4):572-582. PubMed ID: 29129398
[TBL] [Abstract][Full Text] [Related]
5. The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.
de Nóbrega M; Dos Reis MB; Pereira ÉR; de Souza MF; de Syllos Cólus IM
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2893-2910. PubMed ID: 35922694
[TBL] [Abstract][Full Text] [Related]
6. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
Ramnarine VR; Kobelev M; Gibb EA; Nouri M; Lin D; Wang Y; Buttyan R; Davicioni E; Zoubeidi A; Collins CC
Eur Urol; 2019 Nov; 76(5):546-559. PubMed ID: 31445843
[TBL] [Abstract][Full Text] [Related]
7. Emerging Roles of Long Non-coding RNAs as Novel Biomarkers in the Diagnosis and Prognosis of Prostate Cancer.
Kan Y; Li B; Yang D; Liu Y; Liu J; Yang C; Mao L
Discov Med; 2021; 32(165):29-37. PubMed ID: 35219354
[TBL] [Abstract][Full Text] [Related]
8. Radiogenomics in prostate cancer evaluation.
Thenault R; Gasmi A; Khene ZE; Bensalah K; Mathieu R
Curr Opin Urol; 2021 Jul; 31(4):424-429. PubMed ID: 34009176
[TBL] [Abstract][Full Text] [Related]
9. Long non-coding RNAs and prostate cancer.
Misawa A; Takayama KI; Inoue S
Cancer Sci; 2017 Nov; 108(11):2107-2114. PubMed ID: 28796922
[TBL] [Abstract][Full Text] [Related]
10. miRNAs as biomarkers in prostate cancer.
Casanova-Salas I; Rubio-Briones J; Fernández-Serra A; López-Guerrero JA
Clin Transl Oncol; 2012 Nov; 14(11):803-11. PubMed ID: 22855165
[TBL] [Abstract][Full Text] [Related]
11. Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer.
Fitzgerald J; Higgins D; Mazo Vargas C; Watson W; Mooney C; Rahman A; Aspell N; Connolly A; Aura Gonzalez C; Gallagher W
J Clin Pathol; 2021 Jul; 74(7):429-434. PubMed ID: 34117103
[TBL] [Abstract][Full Text] [Related]
12. Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers.
Filella X; Foj L
Int J Mol Sci; 2016 Oct; 17(11):. PubMed ID: 27792187
[TBL] [Abstract][Full Text] [Related]
13. Urinary biomarkers in prostate cancer detection and monitoring progression.
Wu D; Ni J; Beretov J; Cozzi P; Willcox M; Wasinger V; Walsh B; Graham P; Li Y
Crit Rev Oncol Hematol; 2017 Oct; 118():15-26. PubMed ID: 28917266
[TBL] [Abstract][Full Text] [Related]
14. The Potential of MicroRNAs as Prostate Cancer Biomarkers.
Fabris L; Ceder Y; Chinnaiyan AM; Jenster GW; Sorensen KD; Tomlins S; Visakorpi T; Calin GA
Eur Urol; 2016 Aug; 70(2):312-22. PubMed ID: 26806656
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Derived Exosomal Long Noncoding RNAs as Promising Diagnostic Biomarkers for Prostate Cancer.
Wang YH; Ji J; Wang BC; Chen H; Yang ZH; Wang K; Luo CL; Zhang WW; Wang FB; Zhang XL
Cell Physiol Biochem; 2018; 46(2):532-545. PubMed ID: 29614511
[TBL] [Abstract][Full Text] [Related]
16. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
17. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
Nguyen JK; Magi-Galluzzi C
Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
[TBL] [Abstract][Full Text] [Related]
18. Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer.
Valentino A; Reclusa P; Sirera R; Giallombardo M; Camps C; Pauwels P; Crispi S; Rolfo C
Clin Transl Oncol; 2017 Jun; 19(6):651-657. PubMed ID: 28054319
[TBL] [Abstract][Full Text] [Related]
19. Current state of biomarkers for the diagnosis and assessment of treatment efficacy of prostate cancer.
Liu J; Li Y; Yang D; Yang C; Mao L
Discov Med; 2019 Jun; 27(150):235-243. PubMed ID: 31421692
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs Role in Prostate Cancer.
Balacescu O; Dumitrescu RG; Marian C
Methods Mol Biol; 2018; 1856():103-117. PubMed ID: 30178248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
